Eslicarbazepine Acetate Monotherapy Long Term Study

Completed · Phase 3

Conditions studied: Epilepsy

In brief

This is a long term, open-label, safety extension study in subjects with partial onset seizures.

Key facts

Study ID
NCT00910247
Run by
Sumitomo Pharma America, Inc.
People needed
274
Starts
2009-08-01
Expected to finish
2017-04-15
Last updated by the study team
2018-07-17

Who can join

Age: 16 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.